fosfomycin tromethamine / Generic mfg. - LARVOL DELTA

Increased preterm infant gut resistome abundance and diversity with early antibiotic exposure (PAS 2025) - "We analysed metagenome reads from 576 weekly (weeks of life 1-9) faecal samples. A total of 180 ARGs were identified in 523(90.8%) samples. The most frequently identified ARGs included genes conferring resistance to quinolone (oqxB, 70.3%, oqxA, 67.1%), fosfomycin (fosA6, 60%), macrolide (lsaA, 55.6%, ermB, 39.3%), beta-lactam (blaSHV-100, 44.3%, blaSHV-16, 43.6%) and aminoglycoside (aph(2'')-Ia, 37.5%)."

Prematurity • Infectious Disease

Extended spectrum, AmpC & metallo β-lactamases producing Escherichia coli in urinary isolates: A prospective study in north India. (PubMed, Indian J Med Res) - "The E. coli isolates were found to be highly resistant to ciprofloxacin (83.61%), amoxicillin/clavulanate (81.92%), and gentamicin (61%). However, these were sensitive to imipenem (98.3%), fosfomycin (97.17%), and nitrofurantoin (94.35%). Interpretation & conclusions Early detection of various resistance patterns as well as understanding of the local susceptibility patterns among E. coli strains causing UTIs, are imperative for accurate treatment modalities. This knowledge would subsequently contribute to the management of antibiotic resistance and surveillance."

Journal • Infectious Disease • Nephrology

Plasmid-Mediated Colistin and Fosfomycin Resistance among Clinical Isolates of ESBL- and Carbapenemase-Producing Klebsiella Pneumoniae in Northern Iran. (PubMed, Arch Razi Inst) - "The highest resistance rate was observed against ampicillin (97%), chloramphenicol (90%), and ciprofloxacin (87%), respectively.In contrast, the lowest resistance rate was noted against gentamicin (4%), amikacin (10%), and cotrimoxazole (18%). The present study demonstrated that the frequency of K. pneumoniae isolates producing ESBL and carbapenemase, as well as mcr-1, mcr-2 and fosA genes, was relatively low.However,given the potential for these genes to be disseminated more widely, it is imperative to implement effective isolation and control measures. Moreover, these strains demonstrated the capacity to form biofilms in vitro, which can lead to persistent infections in the hospital settings."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases • FOS

Interaction Between HAQ-STING Mutation and COPA: Protection Against COPA Syndrome. (PubMed, Cureus) - "This study provides novel structural insights into the protective role of HAQ-STING in COPA syndrome. The conformational shift induced by HAQ-STING may modulate immune signaling, preventing disease manifestation. A potential binding channel for a small therapeutic molecule was identified at the interface of STING and COPA; fosfomycin was docked in this channel. These findings highlight potential therapeutic avenues, including gene therapy, small-molecule inhibitors, and STING pathway modulation. Further experimental validation is needed to translate these structural insights into clinical applications."

Journal • COPA Syndrome • Gene Therapies • Inflammation • STING

Evaluating the effectiveness of short-term Fosfomycin prophylaxis in prostate biopsy patients: A multicentric prospective study (AUA 2025) - "Short-term, once-daily fosfomycin prophylaxis significantly reduces the incidence of infectious complications following transrectal prostate biopsy. This regimen is particularly advantageous in environments with limited access to transrectal biopsy, reducing infection risks and enhancing patient safety."

Biopsy • Clinical • Infectious Disease • Septic Shock

Single-dose vs prolonged antibiotic prophylaxis of fosfomycin for transrectal prostate biopsy: a single-center prospective, randomized, controlled trial. (PubMed, Prostate Int) - "There is no significant difference in infectious complications between single-dose and prolonged prophylaxis of fosfomycin-trometamol for transrectal prostate biopsy. A single-dose of fosfomycin one hour before biopsy is an ideal choice with a better ecological impact compared with prolonged antibiotic prophylaxis for transrectal prostate biopsy."

Journal • Genito-urinary Cancer • Infectious Disease • Nephrology • Oncology • Prostate Cancer • Solid Tumor • Urology

Description of blaKPC-carrying Escherichia coli in patients from a Brazilian hospital over a 4-year period. (PubMed, Diagn Microbiol Infect Dis) - "Here, we performed a retrospective study in a Brazilian teaching-hospital to describe the genomic features linked to antimicrobial resistance, virulence, and phylogeny of 40 meropenem-resistant E. coli. All isolates carried the blaKPC-2 gene, but amikacin, tigecycline, colistin, polymyxin B, and fosfomycin showed good activity...Whole-genome sequencing identified Tn4401 as a mechanism responsible for blaKPC-2 mobilization, a variety of antimicrobial resistance and virulence genes, the predominance of pathogenic phylogroup lineages, and the grouping of genomes belonging to the same ST. KPC-producing E. coli is not a common pathogen, but few treatment alternatives are available against potentially virulent strains."

Journal • Infectious Disease • Pneumonia

Fosfomycin-resistant Escherichia coli: a FosA10 case in Italy. (PubMed, JAC Antimicrob Resist) - "The patient was treated with piperacillin/tazobactam and, after 10 days, the clinical picture was resolved. The fosA10 gene was carried by a highly conjugative IncB/O/K/Z plasmid that showed relevant similarities with other globally circulating plasmids. The acquisition of rare fosA-like genes in clinically relevant clones is concerning and the dissemination of FosA-producing E. coli should be continuously monitored."

Journal • Infectious Disease

High prevalence of plasmid-mediated Fosfomycin resistance in waterfowl-derived Escherichia coli strains: insights into genetic context and transmission dynamics in China. (PubMed, Front Vet Sci) - "The discovery of plasmid-mediated, transmissible FOS resistance in waterfowl E. coli poses a threat to "One Health". There's an urgent need for thorough monitoring and control measures against FOS resistance."

Journal • Infectious Disease • FOLR1

Comprehensive surveillance of antimicrobial susceptibility across adult and pediatric populations in Catalonia: Insights from community, hospital, and long-term care facility settings. (PubMed, Enferm Infecc Microbiol Clin (Engl Ed)) - "The data underscore the necessity of stratified susceptibility reports by setting, type of infection, and age."

Journal • Infectious Disease • Influenza • Nephrology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Emergence of multidrug resistant Escherichia coli coharboring fosA3 and ESBL genes from retail ducks along slaughter line. (PubMed, Int J Food Microbiol) - "The results indicated that 141 isolates were resistant to fosfomycin and exhibited high resistance to β-lactam antibiotics...Furthermore, 110 virulence factors (VFs) were identified, with those related to iron uptake and storage, adhesion, secretion and endotoxin production being the most prevalent. This study underscored the importance of rational use of antimicrobial agents in poultry farming and provided critical insights into the distribution of ARGs and VFs among retail duck-derived MDR E. coli."

Journal

Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022-2024). (PubMed, Antimicrob Agents Chemother) - "Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates."

Journal

Reinvigorating AMR resilience: leveraging CRISPR-Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security-a systematic review. (PubMed, Trop Med Health) - "CRISPR-Cas technology has the potential to address AMR across priority WHO pathogens. While promising, challenges in optimizing in vivo delivery, mitigating potential resistance, and navigating ethical-regulatory barriers must be addressed to facilitate clinical translation."

Journal • Review • Infectious Disease • Pneumonia

Whole-genome sequencing of extended spectrum beta lactamases (ESBLs)-producing Klebsiella pneumoniae (kp) isolates from selected hospitals in Malaysia. (PubMed, BMC Genomics) - "The study showed that 46(46%) of the 100 isolates were positive for ESBL production and antibiotic susceptibility testing revealed significant resistance to β-lactam antibiotics including monobactam especially ampicillin/sulbactam (40%), cephalosporin groups (cefuroxime, cefotaxime, and ceftriaxone) stood at 51%, 49% and 48% respectively and aztreonam with 49%. The WGS analysis of the representative strains revealed genes encoding resistance to aminoglycoside (StrA4, StrB1, aac(3')-IIa, aac(6')-1b, aac(6')1b-cr-1, aadA16, aph(3')-VIa and aadA15), trimethoprim (dfrA14 and dfrA27), sulphonamide (sul1_11, sul2_2 and sul2_3), quinolone (QnrB40-1, QnrB10, QnrS2, OqxA and OqxB), tetracycline (tet(A)_4), fosfomycin (fosA3, floR2 and fosA7), macrolid (mph(A)_1), rifampicin (ARR-3), β-lactam (blaCTX-M-15_23, blaCTX-M-55, blaSHV-1_22, blaSHV11_18, blaSHV-11, blaSHV-1_1.1, blaSHV-11_3, blaSHV-11_19, blaTEM-1_1, blaTEM-1_5, blaOXA-51_10, blaOXA-30_1, blaNDM-1,..."

Journal • Gene Therapies • Infectious Disease • Pneumonia

Enhanced efficacy of sequential administration of fosfomycin and linezolid against methicillin-resistant Staphylococcus aureus. (PubMed, Front Microbiol) - "TEM analysis further revealed that sequential dosing caused more extensive damage to the bacterial cell wall and nucleus compared to concomitant administration. These findings suggest that sequential administration of fosfomycin and linezolid enhances in vitro efficacy against MRSA and may provide an improved approach for managing complicated and drug-resistant infections."

Journal • Infectious Disease

The Legionella pneumophila peptidoglycan recycling kinase, AmgK, is essential for survival and replication inside host alveolar macrophages. (PubMed, bioRxiv) - "The data show that without AmgK Legionella becomes hypersensitive to Fosfomycin, an antibiotic that targets bacterial cell wall biosynthesis. Moreover, PG recycling is required for Legionella to successfully replicate within a host macrophage. Collectively, the data point to a role of PG recycling in pathogenicity and suggest that inhibiting AmgK could be a powerful strategy in treating Legionnaires' disease."

Journal • Infectious Disease

Adding collagen, Propolis plus quercetin, bacillus coagulans, hyaluronic acid and chondroitin sulphate to D-Mannose avoids symptoms and prevents recurrence in women with recurrent urinary tract infections: a single-blind randomized controlled trial. (PubMed, Expert Rev Anti Infect Ther) - P4 | "To evaluate the efficacy of a new D-mannose dietary supplement containing D-mannose, Propolis-Quercetin, Bacillus Coagulans, Hyaluronic Acid and Chondroitin Sulphate with fosfomycin in reducing rUTI episodes and improving quality of life...Further large-scale studies are recommended to confirm these findings. The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT06659016)."

Journal • Infectious Disease • Nephrology

Genomic plasticity of extensively drug-resistant and multidrug-resistant Acinetobacter baumannii ST208 isolates from a fatal outbreak. (PubMed, J Infect Public Health) - "We identified molecular resistance markers in three XDR and one MDR isolate and provided a genomic description of resistance and virulence, as well as the origins of the isolates. The isolates are closely related to MDRA Oxford ST208 and Pasteur ST2, identified in Asia and Australia. MDRA isolates are of concern in both hospital and community settings in the Western Pacific region."

Journal • Infectious Disease

Fosfomycin and ceftazidime/avibactam combination as a possible treatment for blaIMP-4 harbouring Escherichia coli: a hollow fibre infection model evaluation (ESCMID Global 2025) - No abstract available

Infectious Disease

Analysing uropathogenic Escherichia coli isolates with mutations conferring low-level resistance to quinolones and low-level resistance to fosfomycin (ESCMID Global 2025) - No abstract available

Development of loop-mediated isothermal amplification (LAMP)-based assay for rapid detection of fosfomycin resistance gene (ESCMID Global 2025) - No abstract available

Widespread diversity of fosfomycin resistance gene in Staphylococci: a silent threat (ESCMID Global 2025) - No abstract available

Genetic correlates of synergy mechanisms of daptomycin plus fosfomycin in daptomycin-susceptible and -resistant methicillin-resistant Staphylococcus aureus (ESCMID Global 2025) - No abstract available

Infectious Disease

In vitro antibacterial activity of a fosfomycin/trimethoprim/sulfamethoxazole combination plus anti-mycobacterial agents against reference strains of non-tubercular Mycobacterium spp. (ESCMID Global 2025) - No abstract available

Preclinical

Fosfomycin resistance in Enterobacterales: a one-year surveillance in northern Italy (ESCMID Global 2025) - No abstract available